Indeed, the mechanisms behind the targeted therapies all consider the tumor's unusual genetic and molecular characteristics, as in cases of breast cancer (HER2 positive) and melanoma with BRAF mutations, therefore permitting personalized modes of treatment with reduced damage to normal tissues. This evidence concerns the gene ERBB2 and breast cancer.